Pharmacyclics (PCYC) Tops Q4 EPS by 20c

Pharmacyclics (NASDAQ: PCYC) reported Q4 EPS of $0.96, $0.20 better than the analyst estimate of $0.76. Revenue for the quarter came in at $290 million versus the consensus estimate of $267.5 million.

Worldwide Collaboration and License Agreement with Janssen

Under the Agreement, the repayment of Excess Amounts is contingent and would become payable, with interest, to Janssen from the Company's quarterly share of pre-tax commercial profits, commencing after the third profitable quarter for the collaboration until the total Excess Amounts have been repaid from the Company's earned pre-tax collaboration net profit in subsequent quarters. As of December 31, 2014, total Excess Amounts were $138 million which was comprised of the cumulative amount funded by Janssen to-date of $134 million and interest of $4 million.

For earnings history and earnings-related data on Pharmacyclics (PCYC) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Moody’s raises BJ’s Wholesale outlook to positive on debt reduction
• Moody’s upgrades Brinker to Ba1 on Chili’s growth and debt reduction